Biotech · Private company

Alexion Pharmaceuticals, Inc.

Track this companyFree. Adds Alexion Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials2525 recruiting or active

Pipeline programs18From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline18

ALXN1720Phase 3 · Generalized Myasthenia GravisClinicalTrials.gov · fetched Nov 12, 2026
ALXN1850Phase 3 · HypophosphatasiaClinicalTrials.gov · fetched Nov 12, 2026
ALXN2220Phase 3 · Transthyretin Amyloid Cardiomyopathy (ATTR-CM)ClinicalTrials.gov · fetched Nov 12, 2026
ALXN2220Phase 3 · Transthyretin Amyloid CardiomyopathyClinicalTrials.gov · fetched Nov 12, 2026
asfotase alfaPhase 3 · HypophosphatasiaClinicalTrials.gov · fetched Nov 12, 2026
CAEL-101Phase 3 · AL AmyloidosisClinicalTrials.gov · fetched Nov 12, 2026
cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimenPhase 3 · AL AmyloidosisClinicalTrials.gov · fetched Nov 12, 2026
DanicopanPhase 3 · Paroxysmal Nocturnal HemoglobinuriaClinicalTrials.gov · fetched Nov 12, 2026
RavulizumabPhase 3 · IgANClinicalTrials.gov · fetched Nov 12, 2026
RavulizumabPhase 3 · Neuromyelitis Optica Spectrum DisorderClinicalTrials.gov · fetched Nov 12, 2026
RavulizumabPhase 3 · Generalized Myasthenia GravisClinicalTrials.gov · fetched Nov 12, 2026
RavulizumabPhase 3 · Immunoglobulin A NephropathyClinicalTrials.gov · fetched Nov 12, 2026
RavulizumabPhase 3 · Delayed Graft FunctionClinicalTrials.gov · fetched Nov 12, 2026
ALXN1920Phase 2 · Primary Membranous NephropathyClinicalTrials.gov · fetched Nov 12, 2026
ALXN2030Phase 2 · Antibody-Mediated RejectionClinicalTrials.gov · fetched Nov 12, 2026
ALXN2350Phase 2 · BAG3 Mutation Associated Dilated CardiomyopathyClinicalTrials.gov · fetched Nov 12, 2026
AZD0120Phase 2 · Relapsed AL AmyloidosisClinicalTrials.gov · fetched Nov 12, 2026
UltomirisUltomiris-exposed Pregnant/ PostpartumClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials25

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid CardiomyopathyPHASE3 · NOT_YET_RECRUITING · started Nov 23, 2027ClinicalTrials.gov NCT07789483 · fetched Nov 12, 2026
ALXN2350 in Adult Participants With BAG3-Associated Dilated CardiomyopathyPHASE1_PHASE2 · RECRUITING · started Oct 24, 2025ClinicalTrials.gov NCT07218887 · fetched Nov 12, 2026
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)PHASE2 · RECRUITING · started Sep 19, 2025ClinicalTrials.gov NCT07157787 · fetched Nov 12, 2026
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.PHASE1_PHASE2 · RECRUITING · started Aug 18, 2025ClinicalTrials.gov NCT07081646 · fetched Nov 12, 2026
Study of Ravulizumab in Pediatric Participants With Primary IgANPHASE3 · RECRUITING · started Jun 14, 2025ClinicalTrials.gov NCT07024563 · fetched Nov 12, 2026
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney TransplantationPHASE3 · RECRUITING · started May 19, 2025ClinicalTrials.gov NCT06830798 · fetched Nov 12, 2026
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney TransplantationPHASE2 · ACTIVE_NOT_RECRUITING · started Mar 7, 2025ClinicalTrials.gov NCT06744647 · fetched Nov 12, 2026
Study of Ultomiris® (Ravulizumab) Safety in PregnancyRECRUITING · started Dec 16, 2024ClinicalTrials.gov NCT06312644 · fetched Nov 12, 2026
Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum DisorderNA · ENROLLING_BY_INVITATION · started Nov 12, 2024ClinicalTrials.gov NCT06374264 · fetched Nov 12, 2026
Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum DisorderRECRUITING · started Jul 10, 2024ClinicalTrials.gov NCT06398158 · fetched Nov 12, 2026
Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPPPHASE3 · ACTIVE_NOT_RECRUITING · started May 14, 2024ClinicalTrials.gov NCT06079359 · fetched Nov 12, 2026
Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase AlfaPHASE3 · ACTIVE_NOT_RECRUITING · started Apr 2, 2024ClinicalTrials.gov NCT06079372 · fetched Nov 12, 2026
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)PHASE3 · ACTIVE_NOT_RECRUITING · started Mar 29, 2024ClinicalTrials.gov NCT06291376 · fetched Nov 12, 2026
Study of ALXN2220 Versus Placebo in Adults With ATTR-CMPHASE3 · ACTIVE_NOT_RECRUITING · started Jan 11, 2024ClinicalTrials.gov NCT06183931 · fetched Nov 12, 2026
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase AlfaPHASE3 · ACTIVE_NOT_RECRUITING · started Jan 3, 2024ClinicalTrials.gov NCT06079281 · fetched Nov 12, 2026
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor TherapiesRECRUITING · started Aug 30, 2023ClinicalTrials.gov NCT05966467 · fetched Nov 12, 2026
Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia GravisPHASE3 · ACTIVE_NOT_RECRUITING · started Jun 24, 2023ClinicalTrials.gov NCT05644561 · fetched Nov 12, 2026
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia GravisPHASE3 · ACTIVE_NOT_RECRUITING · started Nov 21, 2022ClinicalTrials.gov NCT05556096 · fetched Nov 12, 2026
A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNHPHASE3 · ACTIVE_NOT_RECRUITING · started Oct 28, 2022ClinicalTrials.gov NCT05389449 · fetched Nov 12, 2026
A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM)ACTIVE_NOT_RECRUITING · started Oct 14, 2022ClinicalTrials.gov NCT05981092 · fetched Nov 12, 2026
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSDPHASE2_PHASE3 · ACTIVE_NOT_RECRUITING · started Jun 23, 2022ClinicalTrials.gov NCT05346354 · fetched Nov 12, 2026
ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening ProgramENROLLING_BY_INVITATION · started May 10, 2021ClinicalTrials.gov NCT05368038 · fetched Nov 12, 2026
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)PHASE3 · ACTIVE_NOT_RECRUITING · started Nov 3, 2020ClinicalTrials.gov NCT04512235 · fetched Nov 12, 2026
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)PHASE3 · ACTIVE_NOT_RECRUITING · started Aug 25, 2020ClinicalTrials.gov NCT04504825 · fetched Nov 12, 2026
Registry of Patients With HypophosphatasiaENROLLING_BY_INVITATION · started Jan 20, 2015ClinicalTrials.gov NCT02306720 · fetched Nov 12, 2026